Industry-university Cooperation Foundation Hanyang University

Chul-Su Yang

Jae-Sung Kim

Tae-Hwan Kim

Yong-Hee Kim

Sun Young Kim

Yoonsung Song

Ye-Ram Kim

So Mi Kim

Jee-Young Chung

Sungsin Jo

Qurrat Ui Ain

The present invention relates to a use of a peptide containing an amino acid sequence represented by SEQ ID NO: 1 derived from the Rv2626c protein offor treating sepsis. The peptide is excellent in inhibiting the inflammatory response induced by macrophages and is excellent in inhibiting the increase in the number of bacterial colonies, and thus can be usefully used for the treatment of sepsis.

Peptide for treating sepsis derived from Rv2626c protein of

The present disclosure is the first to identify a host cell protein and its function with which MPT63 and MPT64, secreted antigens of, interact, and to construct a recombinant MPT protein including each domain of MPT63 and MPT64 interacting with the host cell protein, and the recombinant MPT protein may be applied to a use for the prevention and treatment of tuberculosis by confirming that the recombinant MPT protein targets the-infected macrophages and increases the ROS level and inflammatory cytokine expression in macrophages, thereby inducing the death of. And MPT protein of the present disclosure can improve the vaccine effect by the BCG vaccine so that it can be used as a tuberculosis vaccine and/or vaccine adjuvant either alone or together with known tuberculosis vaccines.

Recombinant MPT protein derived from MPT63 and MPT64 and use thereof

The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, includingGRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function ofGRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly,GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

Pharmaceutical composition for preventing or treating inflammatory diseases includingGRA9 protein or gene encoding the protein as active ingredient

The present invention relates to a novelGRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. TheGRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

GRA8-derived recombinant peptides and composition for preventing or treating cancer comprising the same

Disclosed is a gene/carrier complex for preventing or treating inflammatory diseases, including tumor necrosis factor-&#x3b1; converting enzyme (TNF-&#x3b1; converting enzyme, TACE) shRNA and a nonviral gene carrier, wherein the nonviral gene carrier includes an acetate of disulfide-linked poly(oligo-arginine) or a TFA salt of poly(oligo-aspartic acid)poly(oligo-arginine).

Growing community of inventors

Gyeonggi-do, South Korea

Chul-Su Yang